Contents

Serine Beta LactamaseEdit

Serine beta-lactamases are a diverse family of enzymes that confer resistance to beta-lactam antibiotics by hydrolyzing the characteristic beta-lactam ring. They use a catalytic serine residue in their active site to acylate and then deacylate the antibiotic molecule, effectively inactivating a broad range of penicillins and cephalosporins, and in some cases carbapenems. These enzymes are a major contributor to antibiotic resistance in many clinically important bacteria, particularly among Gram-negative pathogens such as Enterobacterales. Notable members of this family include TEM, SHV, CTX-M, AmpC, and the OXA-type enzymes, each with its own spectrum and inhibition profile. The rise and spread of serine beta-lactamases have driven substantial changes in how infections are treated and how healthcare systems monitor and respond to resistance.

Mechanism and structure

  • Mechanism: Serine beta-lactamases operate through a two-step catalytic process. First, the serine residue in the active site attacks the carbonyl carbon of the beta-lactam ring, forming a covalent acyl-enzyme intermediate and opening the ring. Second, a water molecule, activated by other active-site residues, hydrolyzes the acyl-enzyme complex to release a inactivated antibiotic and regenerate the free enzyme. This rapid catalytic cycle allows many enzymes in this family to neutralize a wide array of beta-lactam substrates.
  • Active-site features: These enzymes rely on conserved residues that coordinate acylation and deacylation steps. The catalytic serine is paired with nearby residues that stabilize reaction intermediates and orient substrates. The precise arrangement of these residues and surrounding loops determines substrate range and inhibitor sensitivity.
  • Structural themes: Serine beta-lactamases share a common alpha/beta fold that supports the catalytic machinery. Although there is diversity across the A, C, and D subclasses, all rely on serine-based chemistry rather than metal ions to hydrolyze beta-lactams.

Classification and major families

  • Ambler classification places serine beta-lactamases in classes A, C, and D. In contrast, class B enzymes are metallo-beta-lactamases that use zinc ions for catalysis. Within the serine group, several clinically important families are distinguished by sequence similarity, substrate profiles, and inhibitor susceptibilities.
  • Notable serine beta-lactamase families:
    • TEM beta-lactamases TEM beta-lactamase: Once among the most widespread plasmid-encoded penicillinases, many variants have expanded activity to include extended-spectrum substrates.
    • SHV beta-lactamases SHV beta-lactamase: A related family with broad activity in various Enterobacterales isolates.
    • CTX-M beta-lactamases CTX-M beta-lactamase: A dominant group worldwide, particularly effective against cefotaxime and other third-generation cephalosporins.
    • AmpC beta-lactamases AmpC beta-lactamase: Often chromosomally encoded and inducible, with plasmid-mediated versions complicating treatment.
    • OXA-type beta-lactamases OXA-type beta-lactamase: A broad family with several variants displaying diverse spectra, including some carbapenemases.
  • Carbapenemases among serine beta-lactamases:
  • Inhibitor susceptibility varies by enzyme class and variant. Some serine beta-lactamases are inhibited by classic beta-lactamase inhibitors (e.g., clavulanic acid, tazobactam, sulbactam), while others show limited sensitivity. Newer inhibitors such as avibactam have broadened therapeutic options against many serine enzymes, though resistance remains a concern.

Inhibitors and therapeutic strategies

  • Traditional inhibitors: Clavulanic acid, tazobactam, and sulbactam are combined with beta-lactam antibiotics to extend activity against some serine beta-lactamases. These inhibitors function by forming an acyl-enzyme or reversible complex that reduces hydrolysis of the antibiotic.
  • Second-generation and newer inhibitors: Avibactam, a non-beta-lactam beta-lactamase inhibitor, is paired with ceftazidime in a widely used combination therapy and can inhibit a broad range of serine beta-lactamases, including many CTX-M and KPC enzymes. Other inhibitor combinations target different spectra to address resistance patterns.
  • Clinical implications: Inhibitor availability and stewardship influence which beta-lactam/β-lactamase inhibitor combinations are employed. The ongoing evolution of beta-lactamases necessitates continuous monitoring of inhibitor efficacy and the development of new agents.

Clinical relevance and surveillance

  • Impact on treatment: The emergence and spread of serine beta-lactamases limit the effectiveness of many frontline antibiotics, complicating therapy for bloodstream infections, pneumonia, urinary tract infections, and hospital-acquired infections.
  • Epidemiology: CTX-M enzymes, TEM/SHV variants, AmpC, and OXA-type enzymes have established distributions that vary by region and healthcare setting. Outbreaks of organisms producing potent serine beta-lactamases often involve plasmid transfers and clonal expansion.
  • Diagnostics: Detection combines phenotypic susceptibility testing with molecular assays. Phenotypic tests may assess inhibition by clavulanate or other inhibitors, while molecular diagnostics identify specific bla genes (e.g., bla_CTX-M, bla_KPC, bla_OXA-48). See diagnostic microbiology and related methods for more detail.
  • Therapeutic considerations: Treatment choices hinge on the specific enzyme profile, organism, infection site, patient factors, and local resistance patterns. This often means using beta-lactamase inhibitor combinations, non-beta-lactam antibiotics, or newer agents designed to overcome resistance.

Evolution, spread, and drivers

  • Gene mobility: Many serine beta-lactamases are carried on plasmids, transposons, and integrons, enabling rapid horizontal transfer between bacteria and across species.
  • Selective pressure: Widespread antibiotic use in medicine and agriculture applies selective pressure that favors organisms harboring efficient serine beta-lactamases, accelerating clonal expansion and diversification.
  • Diversity and surveillance: Ongoing surveillance and genomic analysis help track emergent variants, resistance mechanisms, and transmission pathways, informing infection control and public health strategies.

See also